WESTLAKE VILLAGE, Calif., Nov. 11 /PRNewswire-FirstCall/ -- QT 5, Inc. (BULLETIN BOARD: QTFV) , manufacturer and marketers of NICOWater(TM), the breakthrough Homeopathic Nicotinum (nicotine) product designed to relieve the symptoms of tobacco cravings, today announced it has finalized the exclusive worldwide rights to market an innovative line of rapid-result blood and urine test products. The diagnostic platform has been specifically designed for point-of-care and ambulatory use, as well as providing an ideal development platform for the emerging Homeland Defense market.
The patented test platform incorporates a unique combination of a solid phase membrane and combinations of immunologically based reagents in a single-use disposable test device. The platform has the capacity for providing rapid, point-of-care testing for a wide variety of medical conditions. This diagnostic platform is highly flexible, being capable of testing for a wide variety of important infectious diseases, drugs and their metabolites. Depending upon the application, this platform technology may provide either quantitative or qualitative test results in minutes with a high degree of accuracy.
The current product line includes a number of qualitative and quantitative blood tests that have already received FDA approval. These include qualitative tests that detect within minutes the presence of rubella, herpes virus, rotavirus, strep group A, infectious mononucleosis and early pregnancy.
HIV1 & HIV2 Tests
QT 5, Inc. also announced that it has acquired a 10-minute HIV1 and HIV2 test that is currently in the final stages of FDA Phase 3 testing for ease-of- use. This test procedure represents a significant improvement over currently available diagnostic products that can only detect HIV 1 and take a full 20-minutes before the results are available.
Quantitative Assay Analyzer
QT 5, Inc. will include in its initial product offering, a low-cost small footprint, desktop analyzer designed for use with the rapid test cartridges. The FDA approved analyzer is currently capable of rapidly detecting quantitative data for myoglobin, CK-MB, cardiac troponin-1, as well as the presence and volume of cocaine. A hand held mobile version of the multiple assay analyzer that will be compatible with a wide variety of new tests is also being developed for use by paramedics, assisted living facilities and the military. The mobile assay analyzer will provide a low cost field upgradeable system available for use at point of suspected infection anywhere in the world.
The Company will also include a low-cost rapid result drug test in the initial product line introduction. The test utilizes a rapid immunochromatography assay to detect the presence of drug metabolites in urine. The test is completely self-contained and the results are visibly displayed on the test cup.
According to QT 5, Inc. CEO Timothy Owens, "This is a very exciting new product line that will allow us to continue to grow our business in many of the markets we have been targeting since our very founding. In addition to the exclusive rights for these patented products, we have also secured the right to market these products under the manufacturer's existing US Dept. of Defense and US Dept. of Justice numbers. This will allow us to immediately pursue Federal contracts representing one of the largest potential current and future user bases for these products."
About QT 5, Inc.
QT 5, Inc. is a Delaware corporation formed in April 1999 as a manufacturer, distributor and marketer of biomedical testing and Homeopathic products. QT 5, Inc. currently manufactures and markets NICOWater, its breakthrough Homeopathic Nicotinum (nicotine) product designed to relieve the symptoms of tobacco cravings. QT 5, Inc. continues to do research and development regarding future products for lifestyle enhancements. QT 5, Inc. is headquartered in Westlake Village, California. For more information on the Company please visit: http://www.qt5inc.com/. NICOWater(TM) is a Homeopathic Drug product that is sold under the FDA's Compliance Policy Guide Conditions Under Which Homeopathic Drugs May Be Marketed.
This press release contains forward-looking statements that involve risks, uncertainties and assumptions that, if they never materialize or prove incorrect, could cause the results of QT 5, Inc. to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any projections of earnings, revenue, or other financial items, any statements of the plans, strategies, and objectives of management for future operations, any statements concerning proposed new products, services or developments, any statements regarding future economic conditions or performance, statements of belief and any statements of assumptions underlying any of the foregoing. These statements are based on expectations as of the date of this press release. Actual results may differ materially from those projected because of a number of risks and uncertainties, including those detailed from time to time in the reports filed by QT 5, Inc. with the Securities and Exchange Commission. QT 5, Inc. assumes no obligation and does not intend to update these forward-looking statements.
QT 5, Inc.
CONTACT: Steve Reder, President of QT 5, Inc., +1-818-338-1510,firstname.lastname@example.org; Media - Peter Berk, ext. 205, email@example.com, or J.P.Lincoln, ext. 201, firstname.lastname@example.org, both of Crier Communications,+1-310-274-1072, for QT 5, Inc.